成本效果分析中的行业赞助偏倚:基于注册登记的分析
该注册登记分析纳入1976至2021年Medline发表的8192项成本效果分析(CEA),其中2437项(29.7%)有行业赞助。行业赞助的CEA更可能报告低于5万、10万和15万美元的增量成本效果比(ICER),且在有正增量成本和QALY的CEA中,其ICER较非行业赞助研究低33%(95%CI -40至-26)。结论认为CEA中的赞助偏倚显著、系统性,并存在于多种疾病和研究设计中。
要点
- 8192项CEA中2437项(29.7%)有行业赞助,行业赞助CEA更易报告低于5万、10万、15万美元的ICER。
- 行业赞助CEA报告ICER低于5万、10万、15万美元的调整OR分别为2.06(95%CI 1.82-2.33)、2.95(2.52-3.44)、3.34(2.80-3.99)。
- 在5877项报告正增量成本和QALY的CEA中,行业赞助研究的ICER较非行业赞助研究低33%(95%CI -40至-26)。
核心结论
- CEA中的赞助偏倚显著、系统性,并存在于多种疾病和研究设计中。
- 使用独立机构开展的CEA可能使支付方更有能力谈判更低价格,这对依赖已发表CEA制定保险覆盖政策的国家尤为重要。
研究设计与样本
- 基于注册登记的分析,数据源为Tufts成本效果分析注册登记库,纳入1976至2021年Medline发表的所有CEA。
- 纳入标准为报告使用质量调整生命年(QALY)的增量成本效果比(ICER)并提供足够信息说明ICER大小或位置;共8192项CEA符合条件纳入分析,其中2437项(29.7%)有行业赞助。
- 采用描述性分析比较有和无行业赞助CEA的特征,采用逻辑回归分析行业赞助与成本效果结论(选定阈值5万、10万、15万美元)的关联,采用稳健线性回归评估行业赞助与ICER大小的关联,所有回归分析均调整疾病和研究设计特征。
主要发现
- 行业赞助CEA较非行业赞助研究更可能报告ICER低于5万美元(调整OR 2.06,95%CI 1.82-2.33)、低于10万美元(调整OR 2.95,95%CI 2.52-3.44)和低于15万美元(调整OR 3.34,95%CI 2.80-3.99)。
- 在5877项报告正增量成本和QALY的CEA中,行业赞助研究的ICER较非行业赞助研究低33%(95%CI -40至-26)。
临床怎么用
- 原文未据此给出推荐;作者结论指出,使用独立机构开展的CEA可能使支付方更有能力谈判更低价格,这对依赖已发表CEA制定保险覆盖政策的国家尤为重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between industry sponsorship (drug, medical device, and biotechnology companies) and cost effectiveness results in cost effectiveness analysis (CEA). DESIGN: Registry based analysis DATA SOURCE: The Tufts Cost-Effectiveness Analysis Registry was used to identify all CEAs published in Medline between 1976 and 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: CEAs that reported incremental cost effectiveness ratio (ICER) using quality adjusted life year and provided sufficient information about the magnitude or location of the ICER. METHODS: Descriptive analyses were used to describe and compare the characteristics of CEAs with and without industry sponsorship. Logistic regression was used to identify the association between industry sponsorship and the cost effective conclusion using selected threshold values ($50 000 (£40 511; €47 405), $100 000, and $150 000). Robust linear regression was used to assess the association between industry sponsorship and the magnitude of ICER. All regression analyses were adjusted for disease and study design characteristics. RESULTS: 8192 CEAs were eligible and included in the analysis, with 2437 (29.7%) sponsored by industry. Industry sponsored CEAs were more likely to publish ICERs below $50 000 (adjusted odds ratio 2.06, 95% confidence interval 1.82 to 2.33), $100 000 (2.95, 2.52 to 3.44), and $150 000 (3.34, 2.80 to 3.99) than non-industry sponsored studies. Among 5877 CEAs that reported positive incremental costs and quality adjusted life years, ICERs from industry sponsored studies were 33% lower (95% confidence interval -40 to -26) than those from non-industry sponsored studies. CONCLUSIONS: Sponsorship bias in CEAs is significant, systemic, and present across a range of diseases and study designs. Use of CEAs conducted by independent bodies could provide payers with more ability to negotiate lower prices. This impartiality is especially important for countries that rely on published CEAs to inform policy making for insurance coverage because of limited capacity for independent economic analysis.
引用
- Xie F, Zhou T. Industry sponsorship bias in cost effectiveness analysis: registry based analysis. BMJ. 2022. PMID: 35732297. doi:10.1136/bmj-2021-069573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。